The research, led by Shuhan Lv and Qian Chen and their colleagues, focused on Olfr544 for a compelling reason. Previous work had shown that this receptor is highly expressed in the cerebral cortex and hippocampus of nine-month-old 5×FAD transgenic mice, a widely used model of Alzheimer’s disease. Its expression localizes near amyloid-beta plaques, the pathological hallmark of the disease, and its mRNA levels fluctuate with both age and disease progression. That pattern alone would be intriguing, but Olfr544 also belongs to a small club of olfactory receptors that have been deorphanized, meaning scientists know their chemical activator. In this case, the trigger is azelaic acid, a naturally occurring dicarboxylic acid that has already been implicated in metabolic regulation elsewhere in the body, including glucagon secretion in pancreatic alpha cells, lipolysis, and mitochondrial biogenesis in skeletal muscle. What remained entirely unknown was the receptor’s function inside the nervous system.

To probe that function, the team turned to the mouse neuroblastoma cell line N2a, a standard workhorse for studying neuronal differentiation and neurite extension. Their first task was to confirm that these cells genuinely possess the machinery for Olfr544 signaling. Using reverse transcription polymerase chain reaction followed by agarose gel electrophoresis and DNA sequencing, they demonstrated that N2a cells endogenously express not just Olfr544 itself but also its canonical downstream partners, the olfactory G protein Gαolf and adenylyl cyclase 3. That trio constitutes the full signaling axis that olfactory receptors use in the nose, and its presence in neuronal cells suggested that Olfr544 could operate as a functional GPCR in the brain rather than sitting there as molecular decoration.

The functional experiments began with azelaic acid. After establishing with an MTT assay that concentrations up to 640 micromolar had no effect on N2a cell viability, the researchers treated serum-deprived cultures with 500 micromolar of the compound for 24 hours. Under phase-contrast microscopy, the effect was unmistakable. Roughly 30 percent of treated cells extended neurites, defined as processes longer than the cell body’s diameter, compared with only about 10 percent of serum-deprived controls. Because short-term serum deprivation itself modestly promotes neurite outgrowth, the azelaic acid effect represented a genuine, receptor-linked enhancement of neuronal differentiation. Direct morphological comparison with receptor-deficient cells proved technically awkward because Olfr544 knockout cells grow and adhere poorly even at baseline, so the team pivoted to a cleaner strategy: dissect the downstream signaling and transcriptional consequences of receptor loss.

Before those genetic experiments, the researchers sought independent confirmation that Olfr544 is sufficient, on its own, to drive CREB-dependent transcription. They cloned the full-length mouse Olfr544 cDNA into a specialized expression vector that promotes proper membrane trafficking of olfactory receptors, then co-transfected it into HEK293T cells, which lack endogenous Olfr544, together with a CREB-responsive dual-luciferase reporter. When azelaic acid was added, luciferase activity surged in receptor-expressing cells but stayed flat in empty-vector controls. Co-treatment with SQ22536, an inhibitor of adenylyl cyclase, markedly blunted the response, confirming that the signal flowed through cAMP production. This heterologous reconstitution ruled out the possibility that azelaic acid’s effects in neuronal cells depend on indirect pathways unique to the N2a environment, and it established a direct mechanistic line from receptor to transcription factor.

The genetic core of the study came from CRISPR-Cas9 editing. The team designed two single-guide RNAs targeting exon 2 of the mouse Olfr544 gene, transfected them into N2a cells, selected edited populations with puromycin, and isolated monoclonal lines by limiting dilution. Sanger sequencing confirmed a homozygous 149-base-pair deletion that introduces a frameshift and a premature stop codon, and reverse transcription PCR showed loss of the wild-type transcript, consistent with nonsense-mediated decay. The authors candidly note that no validated specific antibody existed to confirm receptor loss at the protein level, a limitation they flag explicitly. Still, the functional evidence was decisive. When wild-type N2a cells were stimulated with 50 micromolar azelaic acid for 30 minutes, levels of phosphorylated CREB, the transcription factor that sits at the crossroads of neuronal survival, plasticity, and memory formation, rose significantly. In knockout cells, that increase vanished entirely, while basal pCREB remained unchanged, proving that azelaic acid’s activation of CREB is strictly Olfr544-dependent.

The team then traced the pathway upstream of CREB. Canonical GPCR signaling proceeds through Gαs proteins to activate adenylyl cyclase, elevate intracellular cAMP, and stimulate protein kinase A, which in turn phosphorylates CREB. Enzyme-linked immunosorbent assays showed that azelaic acid triggered a rapid rise in intracellular cAMP in wild-type cells, though a smaller one than forskolin, a direct adenylyl cyclase activator, could produce. In knockout cells, the cAMP response to azelaic acid was completely abolished, and PKA activity followed the same pattern, rising with drug treatment in wild-type cells but not in receptor-deficient ones. Together, these measurements delineate a clean linear cascade: Olfr544 activation, cAMP elevation, PKA activation, CREB phosphorylation. It is the textbook GPCR framework, operating in a neuronal context and converging on a transcription factor that governs synaptic plasticity.

To see what genes this cascade controls, the researchers performed RNA sequencing on wild-type and Olfr544 knockout cells, generating more than 41 gigabytes of clean data with mapping rates between 86 and 95 percent. Differential expression analysis identified 1,727 genes whose expression changed, 1,397 upregulated and 330 downregulated. Enrichment analysis revealed a striking asymmetry. Upregulated genes clustered in the neuroactive ligand-receptor interaction pathway, involving 41 genes encoding GPCRs and ion channels, which the authors interpret as possible compensatory mechanisms. Downregulated genes were concentrated in the motor protein pathway, including members of the myosin, actin, and kinesin families. That downregulation is precisely what one would expect if Olfr544 supports neurite dynamics, because motor proteins are essential for the cytoskeletal remodeling that drives process extension and neuronal morphogenesis. The authors caution that the transcriptomic comparison used a single monoclonal knockout line, so the results should be read as hypothesis-generating candidate pathways rather than a definitive catalog of receptor targets.

From the downregulated genes, computational prediction of CREB binding sites flagged three high-confidence candidates: Igf2bp3, Sorbs2, and Kctd14. Independent validation in the unedited parental cell line strengthened the case, particularly for IGF2BP3, an mRNA-binding protein implicated in axon guidance and synaptic plasticity. Its protein level rose significantly with azelaic acid treatment in wild-type cells and was markedly reduced in knockout cells, with no rescue by the agonist, making it the most robust Olfr544-dependent effector identified. SORBS2, which maintains dendritic complexity and synaptic integrity, and KCTD14, a member of a family linked to neurodevelopmental disorders, showed consistent downward trends in knockout cells, though not every pairwise comparison reached statistical significance. The authors are careful to note that the link between CREB activation and these targets remains correlative and that chromatin immunoprecipitation studies will be needed to confirm direct transcriptional regulation.

The bigger picture is what makes this work resonate beyond the cell culture hood. Olfactory receptors account for roughly 60 percent of human GPCRs, and mounting evidence ties their brain expression to Alzheimer’s disease, Parkinson’s disease, and schizophrenia, with some receptors modulating microglial phagocytosis or tau phosphorylation. This study establishes, for the first time, a direct linear signaling axis connecting a brain-expressed olfactory receptor to the structural machinery of the neuron itself. It also hints at a possible bridge to tau biology, since a homolog of IGF2BP3 binds tau mRNA and IGF2BP3 variants correlate with tau burden in Alzheimer’s patients. The authors are appropriately restrained about the disease connection, emphasizing that their findings are in vitro and that the relevance to Alzheimer’s pathology remains speculative. Future work, they argue, should test Olfr544 in knockout and transgenic mouse models, identify the receptor’s endogenous brain ligands, and determine whether modulating the pathway affects synaptic integrity, neurodegeneration, or cognition. If those experiments pan out, a receptor once thought to exist solely to smell the world may turn out to be a lever for protecting the brain from one of its most devastating diseases.

Subject of Research: The role of the extra-olfactory olfactory receptor Olfr544 in neuronal neurite outgrowth and CREB signaling

Article Title: Role of olfactory receptor Olfr544 in neuronal cells: Insights into neurite outgrowth and CREB signaling

Article References: Lv, S., Liu, J., Zhou, Y., Yang, R., Zhang, T., Deng, Y., Chen, Y., Lai, C., & Chen, Q. (2026). Role of olfactory receptor Olfr544 in neuronal cells: Insights into neurite outgrowth and CREB signaling. iScience, 29(11), Article 117757. https://doi.org/10.1016/j.isci.2026.117757

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117757

Keywords: olfactory receptors, Olfr544, azelaic acid, CREB signaling, neurite outgrowth, N2a cells, cAMP, PKA, CRISPR-Cas9, Alzheimer's disease, GPCR, IGF2BP3

The clinical starting point was a group of patients whose stomachs suffer as a consequence of their livers. The team enrolled 111 patients with hepatitis B-related liver cirrhosis or hepatic failure at the Third Affiliated Hospital of Sun Yat-sen University between January 2022 and August 2024, alongside 118 control subjects. Using the gastrointestinal symptom rating scale, a validated 15-item questionnaire, the researchers found that patients with liver disease scored significantly higher overall than controls, 51.49 versus 42.40, with heartburn, acid reflux, nausea, bloating and diarrhea all markedly more frequent. Endoscopy told a matching story: the diseased mucosa showed more erosion and bleeding, and statistical analysis confirmed that mucosal lesions correlated with higher symptom scores, while normal mucosa tracked with lower scores.

Why would a congested stomach become a hypoxic one? The explanation is vascular. In portal hypertension and hepatic failure, restricted blood flow through the portal vein causes gastric venous congestion, and the oxygen supply to the epithelium falls behind demand. Using Hypoxyprobe-1 staining, the team demonstrated that hypoxia was indeed present in the gastric epithelium of these patients. In parallel, they established a mouse model of portal hypertension by partially ligating the portal vein, and again the hypoxia signal rose in step with a quantified gastric injury index. Crucially, the transcription factor HIF-1α, the master regulator of the cellular response to low oxygen, accumulated in the nuclei of epithelial cells in both human and mouse tissue, poised to reprogram gene expression.

That reprogramming showed up first as a metabolic shift. RNA sequencing of clinical gastric samples revealed enrichment of glycolysis and anaerobic metabolism pathways, and untargeted metabolomics of epithelial cells from the mouse model confirmed the biochemical signature: lactic acid rose while isocitric acid and citric acid, intermediates of the mitochondrial citric acid cycle, fell. This is the classic Warburg-like pattern in which cells, deprived of the oxygen needed for oxidative phosphorylation, burn glucose to lactate instead. In the short term this is a survival strategy, but the study suggests that under sustained hypoxia it becomes pathological, feeding a vicious cycle of metabolic disorder, reactive oxygen species generation and cell death.

The central molecular discovery concerns FUNDC1, an outer mitochondrial membrane protein previously known to help build mitochondria-associated ER membranes, or MAMs. These contact sites are far more than structural curiosities: they regulate calcium transfer from the ER to mitochondria, lipid exchange and mitochondrial dynamics. The researchers found that HIF-1α binds directly to a hypoxia-responsive element in the FUNDC1 promoter, driving its transcription, and that a second, post-transcriptional layer reinforces this. The m6A methyltransferase METTL3 chemically modified FUNDC1 messenger RNA, and the RNA-binding protein IGF2BP3, the most upregulated m6A reader in cirrhotic gastric tissue, recognized and stabilized that modified transcript. In mice carrying a mutant METTL3, FUNDC1 upregulation was blunted, confirming the epitranscriptomic mechanism.

With FUNDC1 elevated, the ER and mitochondria embraced more tightly. Transmission electron microscopy showed expanded contact zones in epithelial cells from portal hypertensive mice and from cirrhotic patients, and a proximity ligation assay for the IP3R2–VDAC1 tethering pair quantified the same increase. Coimmunoprecipitation confirmed that FUNDC1, IP3R2, VDAC1 and GRP75 formed complexes under hypoxic conditions. Truncation experiments pinpointed amino acids 7 to 48 of FUNDC1 as the domain essential for MAMs formation, a detail the authors highlight as a blueprint for designing inhibitors that could block the tethering interface specifically.

The consequences of this hyper-tethering were metabolic and oxidative. Seahorse extracellular flux analysis showed that epithelial cells under hypoxia had reduced maximal respiration, increased proton leak, elevated non-mitochondrial oxygen consumption and heightened basal and compensatory glycolysis, all of which were reversed when FUNDC1 was knocked down. Levels of electron transport chain subunits NDUFA9, SDHA, cytochrome b and ATP5A fell, along with ATP production. Meanwhile, mitochondrial superoxide, lipid peroxidation products such as 4-HNE and malondialdehyde, and oxidized mitochondrial DNA all climbed, while antioxidant defenses, superoxide dismutase activity and the glutathione redox ratio, collapsed. Calcium handling was also disturbed, with both cytosolic and mitochondrial calcium rising and membrane potential falling.

The final executioner in the cascade was NINJ1, a transmembrane protein that has recently emerged as the mediator of plasma membrane rupture during lytic cell death. In its inactive state NINJ1 is scattered across the membrane; when activated it oligomerizes into polymers that lyse the membrane and spill cellular contents. The team found NINJ1 oligomerization increased in gastric tissue from cirrhotic and hepatic failure patients, alongside elevated cleaved caspase-3 and cleaved caspase-1, markers of apoptosis and pyroptosis. Silencing NINJ1 in mice with portal hypertension reduced lactate dehydrogenase release, a readout of membrane permeabilization, restored epithelial viability and lessened mucosal injury. Notably, NINJ1 blockade did not change caspase activation, indicating it acts at the terminal step of membrane rupture rather than upstream of cell death signaling.

Two intervention experiments tied the whole axis together and pointed toward the clinic. Mito-TEMPO, a mitochondria-targeted antioxidant, suppressed NINJ1 oligomerization, reduced LDH release and protected the gastric mucosa in the mouse model, placing mitochondrial reactive oxygen species upstream of NINJ1 activation. The HIF-1α inhibitor PX-478 suppressed FUNDC1 expression and attenuated injury. Confocal imaging also showed that fragmented mitochondrial DNA released under oxidative stress colocalized with NINJ1, hinting at a direct or indirect role for escaping mtDNA in activating the rupture machinery, though the authors acknowledge the precise mechanism remains unresolved.

The authors are candid about limitations. The partial portal vein ligation model mechanically constricts the portal vein without reproducing hepatic parenchymal injury, systemic inflammation or the other comorbidities of clinical cirrhosis, and only knockdown rather than tissue-specific knockout approaches were used. Yet the reversibility of the pathway is encouraging: because MAMs remodeling is dynamic rather than covalent, targeted disruption of excessive ER-mitochondria tethering, inhibition of METTL3 or IGF2BP3 with emerging small molecules, or blockade of NINJ1 oligomerization with monoclonal antibodies could, in principle, interrupt the cycle before irreversible tissue damage sets in. If those strategies survive preclinical and clinical testing, the humble contact points between two organelles may become the address at which doctors finally treat the stomach’s silent suffocation.

Subject of Research: The FUNDC1–MAMs–NINJ1 signaling axis in hypoxia-induced gastric mucosal injury

Article Title: Mitochondria-associated endoplasmic reticulum membranes facilitate gastric epithelial injury in hypoxia-induced gastric mucosal lesions

Article References: Tan, S., Luo, J., Ou, X., Guo, X., Ke, B., & Tan, S. (2026). Mitochondria-associated endoplasmic reticulum membranes facilitate gastric epithelial injury in hypoxia-induced gastric mucosal lesions. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.007

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.007

Keywords: hypoxia, gastric mucosal injury, mitochondria-associated ER membranes, FUNDC1, HIF-1α, m6A methylation, METTL3, IGF2BP3, NINJ1, portal hypertension, mitochondrial oxidative stress, plasma membrane rupture

The Balbiani body, often abbreviated as the B-body or Bb, is a cloud of RNA, proteins, and organelles that appears in the cytoplasm of young oocytes across a striking range of animals, from fruit flies to frogs to humans. Although its existence has been known since the nineteenth century, its exact molecular recipe has remained elusive, particularly outside a handful of classic model organisms. In fish, another related structure called nuage—a diffuse, electron-dense material associated with germ cells—complicates the picture. Both structures are membraneless, which means they cannot simply be plucked out of a cell with conventional biochemical tools, and their components intermingle with the surrounding cytoplasm in ways that frustrate isolation.

To overcome this technical barrier, the team led by Ji Liu, Xi Wu, and Jian Luo of Hainan University turned to laser capture microdissection, a technique that uses a precision laser to excise specific regions from tissue sections mounted on a microscope slide. Working with the Leica LMD7000 system at the Ocean University of China, the researchers carved out the Balbiani body region from oocytes at different developmental stages. Because the nuage proved too difficult to isolate reliably on its own, they instead dissected the nucleus together with the surrounding nuage, creating what they call a nuage-associated nucleus-containing region, or NNR. This pragmatic compromise allowed them to profile the nuage neighborhood while acknowledging that nuclear molecules would inevitably contaminate the signal.

The ultrastructural work, carried out with electron microscopy, established the timeline of events. Nuage material was present from the earliest oogonial stages and persisted throughout oocyte development. The Balbiani body, by contrast, made its appearance specifically in primary oocytes, where it gradually expanded before dispersing its contents into the surrounding cytoplasm. This choreography—formation, expansion, and dispersion—mirrors what has been described in other species and suggests a conserved role in preparing the egg with maternal materials that the early embryo will depend on before its own genes switch on.

On the molecular side, the researchers applied Smart-seq2, a highly sensitive method for sequencing the RNA of individually captured cells or compartments, alongside data-independent acquisition proteomics, or DIA, which quantifies thousands of proteins in a sample by systematically fragmenting all peptides within defined mass windows. Running both technologies on the same microdissected regions allowed the team to compare the transcriptomic and proteomic landscapes directly. The result was revealing: across the different Balbiani body stages, RNA levels changed relatively little, but the protein complement shifted much more dramatically. This decoupling suggests that post-transcriptional regulation—proteins being made, modified, or degraded without corresponding changes in messenger RNA—dominates the maturation of the granule, a theme that resonates with the B-body’s known function as a site of stored, translationally repressed maternal transcripts.

The NNR samples, meanwhile, showed molecular variation that tracked with developmental stage, consistent with the changing composition of the nuage that surrounds the nucleus as oocytes age. The compartment-biased expression of established marker molecules matched what is already known about Balbiani body biology, lending confidence to the microdissection strategy. The authors are careful, however, to flag the limits of the NNR data: because the dissected region includes the nucleus, any functional signals detected there must be treated as exploratory rather than definitive. Nuclear transcripts and proteins inevitably dominate such samples, and disentangling genuine nuage components from nuclear background will require more refined approaches in future work.

Perhaps the most consequential finding of the study is the identification and validation of two candidate Balbiani body markers: Ddx6 and Igf2bp3. Ddx6 encodes a DEAD-box RNA helicase, a class of enzymes best known for remodeling RNA structures and regulating translation, and it has well-documented roles in germ granules across the animal kingdom. Igf2bp3, a member of the insulin-like growth factor 2 mRNA-binding protein family, is an oncofetal RNA-binding protein that has been implicated in RNA localization and stability. In the grouper oocytes, both the messenger RNAs and the proteins corresponding to these two genes localized precisely to the Balbiani body region under the microscope. Even more strikingly, their localization shifted over time in lockstep with the granule’s own life cycle—appearing as the B-body formed, tracking its expansion, and dispersing as the structure dissolved into the cytoplasm.

This stage-dependent co-localization makes Ddx6 and Igf2bp3 valuable new tools for the field. Reliable markers are the currency of organelle biology: they allow researchers to track a structure’s dynamics in live tissue, to test whether candidate interactors genuinely join the compartment, and to compare granule composition across species and developmental contexts. For fish, where the Balbiani body has been far less characterized than in frogs or flies, adding two validated markers to the repertoire represents a meaningful expansion of the experimental toolkit. It also opens the door to functional studies—knockdown or knockout experiments could now ask what happens to oocyte quality and embryonic development when these granule components are removed.

The choice of species matters as much as the methods. The leopard coral grouper, Plectropomus leopardus, is one of the most prized reef fish in Asian aquaculture, and its seed production depends on high-quality eggs whose developmental potential is laid down during oogenesis. Understanding the molecular machinery that packages maternal determinants into the oocyte could eventually inform hatchery practices, broodstock management, and breeding programs. The study was supported by funding from the Sanya Yazhou Bay Science and Technology City project, the National Natural Science Foundation of China’s Regional Innovation and Development Joint Fund, and several Hainan provincial programs, reflecting the region’s investment in marine breeding science.

Beyond aquaculture, the work speaks to a broader question in cell biology: how membraneless compartments, held together by weak multivalent interactions rather than lipid bilayers, achieve precise composition and timing. The Balbiani body is a natural model for this problem, assembling at a specific place and time, carrying a defined cargo, and then dissolving on schedule. By pairing spatially resolved microdissection with dual transcriptomic and proteomic profiling, the grouper study demonstrates a framework that other researchers can adapt to any tissue where membraneless granules are too small or too intermingled for conventional purification. The authors themselves emphasize that the nuage remains the next frontier—its molecular composition, and its possible relationship with the Balbiani body, await isolation methods sharp enough to capture it alone. Until then, the dynamic portrait of Ddx6 and Igf2bp3 tracing the granule’s rise and fall offers a vivid glimpse of how an egg builds the seed of an embryo, one molecular granule at a time.

Subject of Research: Molecular characterization of Balbiani body formation during oocyte development in leopard coral grouper

Article Title: Integrative analysis of Smart-seq2 and DIA proteomics reveals dynamic formation of the Balbiani body during oocyte development in leopard coral grouper (Plectropomus leopardus)

Article References: Liu, J., Wang, G., Zhang, X., Wu, X., Zhang, X., Zheng, T., Wen, X., Wu, X., & Luo, J. (2026). Integrative analysis of Smart-seq2 and DIA proteomics reveals dynamic formation of the Balbiani body during oocyte development in leopard coral grouper (Plectropomus leopardus). BMC Genomics. https://doi.org/10.1186/s12864-026-13414-2

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13414-2

Keywords: Balbiani body, oocyte development, nuage, laser capture microdissection, Smart-seq2, DIA proteomics, Ddx6, Igf2bp3, leopard coral grouper, germ granules, oogenesis, membraneless organelles

The tagging system in question is N6-methyladenosine, abbreviated m6A, the most abundant internal chemical modification found in the messenger RNA of higher organisms. Far from being a decorative flourish, m6A acts as a master regulator of RNA metabolism, influencing nearly every step of an RNA molecule’s life: how it is processed, exported from the nucleus, translated into protein, and ultimately degraded. The modification is installed by a writer complex whose core components include the enzymes METTL3 and WTAP, removed by eraser proteins, and interpreted by reader proteins such as IGF2BP3, which can stabilize methylated transcripts and protect them from destruction. Because m6A touches so many aspects of gene regulation, disruptions to this system have been implicated in a wide range of human cancers, making it one of the most intensely studied frontiers in molecular oncology.

What has remained murky, the researchers note, is how tumors balance the methylation and demethylation of their RNA when oxygen becomes scarce, and what the consequences of that balance are for pancreatic neuroendocrine neoplasms specifically. These tumors, often abbreviated pNENs, have attracted growing clinical attention because their incidence has been rising, yet the molecular drivers of their proliferation and spread remain incompletely understood. The new study set out to close that gap by examining what happens to m6A levels in pNEN cells exposed to hypoxic conditions that mimic the interior of a solid tumor.

The answer came quickly and dramatically. When pNEN cells were placed under hypoxia, the team documented a significant reduction in overall m6A levels, and the magnitude of this loss correlated with the advancement of the disease. In other words, the more the RNA methylation landscape was eroded by low oxygen, the more aggressive the tumors became. This observation framed a central mechanistic question: what molecular chain of events connects an environmental cue, the lack of oxygen, to a chemical change on RNA, and finally to the malignant behavior of the cell?

The first link in the chain proved to be a protein called USP38, a deubiquitinase whose normal job is to remove ubiquitin tags from other proteins and thereby shield them from degradation. The researchers found that hypoxia suppresses USP38 in pNEN cells. With USP38 out of the picture, two critical members of the m6A writer machinery, METTL3 and WTAP, became vulnerable to ubiquitination, the cellular process that flags proteins for destruction by the proteasome. Stripped of their protective deubiquitinase, METTL3 and WTAP were degraded, and the cell’s capacity to install m6A marks on its messenger RNA collapsed. It is an elegant example of biological economy: rather than shutting down the methylation enzymes one by one, the hypoxic tumor cell removes their bodyguard and lets the cell’s own waste-disposal system do the work.

With the writer complex disabled, the downstream consequences unfolded through a reader protein. The reduction in m6A modification, the study found, was mediated through IGF2BP3, one of the best-characterized m6A readers. IGF2BP3 typically binds methylated transcripts and prolongs their survival, so when methylation levels fall, its stabilizing grip loosens. The critical target transcript in this case was the messenger RNA encoding TGFBI, a secreted matrix protein whose name derives from transforming growth factor beta-induced. Under hypoxic conditions, the loss of m6A marks led to decreased stability of TGFBI mRNA, meaning the transcript was degraded faster and less TGFBI protein was produced. Hypoxia, in effect, was turning down the volume on a specific gene through an RNA-level mechanism rather than by altering the gene itself.

What makes this finding particularly striking is what TGFBI does next. The researchers demonstrated that TGFBI binds directly to Integrin beta 1, a cell-surface receptor that anchors cells to their surrounding matrix and transmits signals inward, and that TGFBI normally exerts a negative regulatory effect on ITGB1. When hypoxia drives TGFBI down, that brake is released. Integrin beta 1 expression rises in the pNEN cells, and with it comes activation of the Integrin/FAK signaling pathway, a canonical axis in which focal adhesion kinase relays cues from the cell surface to the interior, fueling proliferation, survival, motility, and metastatic behavior. The tumor cell, starved of oxygen, effectively rewires its own adhesion and signaling apparatus to grow faster and spread further.

Taken together, the pathway described by the team runs like a relay: hypoxia silences USP38, which permits the ubiquitination and destruction of METTL3 and WTAP; methylation of RNA falls; IGF2BP3 loses its hold on TGFBI mRNA, which destabilizes; TGFBI protein declines; Integrin beta 1 is released from repression; and the Integrin/FAK pathway surges, driving the proliferation and metastasis that define aggressive pNEN progression. Each node in this cascade is a potential point of intervention, and the authors suggest that their findings offer novel therapeutic targets for a tumor type that has long lacked precision options. Blocking the degradation of the writer complex, stabilizing TGFBI, or dampening Integrin/FAK signaling could each, in principle, sever the chain that links oxygen deprivation to malignancy.

The study also contributes to a broader conceptual shift in cancer biology. For decades, tumor research focused on mutations in DNA, permanent changes in the genetic code that drive cancer. Work like this underscores that the chemical decoration of RNA, which is dynamic and reversible, constitutes an equally powerful regulatory layer that tumors can manipulate in response to their environment. Hypoxia is one of the most universal stresses in solid tumors, and the discovery that it can reprogram the m6A landscape of pancreatic neuroendocrine neoplasms adds a mechanistic bridge between a well-known feature of the tumor microenvironment and the epitranscriptomic machinery that executes the cell’s adaptive response. It also explains why tumors that experience chronic oxygen deprivation may behave so differently from their well-oxygenated counterparts, even when their genomes are otherwise similar.

For patients with pancreatic neuroendocrine neoplasms, the clinical significance of these findings could be considerable. Current treatments, including surgery, somatostatin analogs, targeted agents, and peptide receptor radionuclide therapy, are effective for many but fall short in advanced disease. A validated understanding of the hypoxia-m6A-TGFBI-Integrin/FAK axis offers a molecular map for developing diagnostics, since m6A levels or TGFBI abundance could potentially serve as biomarkers of tumor aggressiveness, and for designing drugs that interrupt the pathway at its most vulnerable links. The work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Jiangsu Province, and other regional funding bodies, and it was conducted with institutional ethical approval for both animal studies and the use of discarded human tumor tissue. As with all mechanistic laboratory research, translating these findings into bedside applications will require further validation, but the study provides something increasingly rare and valuable in oncology: a complete, coherent chain of cause and effect running from the air a tumor breathes to the genes it expresses and the damage it ultimately inflicts.

Subject of Research: How hypoxia regulates m6A RNA methylation of TGFBI to activate Integrin/FAK signaling in pancreatic neuroendocrine neoplasms

Article Title: Hypoxia down-regulates METTL3 and WTAP activating Integrin/FAK signaling through m6A/IGF2BP3 dependent manners in TGFBI mRNA to promote pancreatic neuroendocrine neoplasms progression

Article References: Liu, P., Lu, F., Hu, C., Chen, J., Han, X., Bao, J., Sun, W., Xu, Y., Zhou, G., Yang, X., Chen, F., & Ye, M. (2026). Hypoxia down-regulates METTL3 and WTAP activating Integrin/FAK signaling through m6A/IGF2BP3 dependent manners in TGFBI mRNA to promote pancreatic neuroendocrine neoplasms progression. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06452-2

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06452-2

Keywords: pancreatic neuroendocrine neoplasms, hypoxia, m6A methylation, METTL3, WTAP, IGF2BP3, TGFBI, Integrin/FAK pathway, USP38, RNA modification, cancer metastasis, tumor microenvironment

The messenger RNA in question encodes CENPA, or centromere protein A, a specialized histone variant that performs a task no dividing cell can do without: it marks the centromere, the chromosomal anchor point that spindle fibers grip during mitosis to ensure chromosomes are partitioned faithfully between daughter cells. CENPA has long been known to be elevated in a range of tumors, where excess levels contribute to chromosomal instability, aberrant cell division, and aggressive behavior. The new study adds an important layer to that picture by showing that in bladder urothelial carcinoma, CENPA abundance is not simply a matter of how much mRNA is transcribed from the gene, but how long that mRNA survives once it is made—and that survival is controlled by a discrete epitranscriptomic mark.

That mark is N6-methyladenosine, or m6A, the most prevalent internal modification in eukaryotic messenger RNA. Rather than changing the genetic sequence itself, m6A tags act like postal codes, dictating how each transcript is folded, exported, translated, or degraded. The system depends on reader proteins that recognize the tag and act on it. Among the most consequential readers is the IGF2BP family, and in particular IGF2BP3, also known as IMP3, an oncofetal RNA-binding protein that is largely silenced in adult tissues but re-emerges in many cancers, including glioma, hepatocellular carcinoma, renal cell carcinoma, and bladder cancer. Prior work had already linked IGF2BP3 to tumor progression and stem-like behavior in bladder cancer, but its precise contribution to chemotherapy resistance had remained murky.

To dissect that contribution, the research team turned to a pair of well-characterized human bladder urothelial carcinoma cell lines, UMUC3 and T24, alongside a purposefully derived paclitaxel-resistant counterpart of T24, designated T24/R. Paclitaxel works by stabilizing microtubules, throwing a wrench into the mitotic spindle and triggering cell death in rapidly dividing cells. Resistant cells must therefore either alter their division machinery or blunt the death pathways that spindle catastrophe activates. Using a battery of molecular assays—RNA immunoprecipitation to capture physical protein-RNA interactions, methylated RNA immunoprecipitation followed by quantitative PCR to detect the m6A mark itself, and dual-luciferase reporter assays to confirm sequence-specific binding—the researchers established that IGF2BP3 directly recognizes m6A-modified CENPA mRNA in bladder cancer cells.

The functional consequences of that recognition were striking. When the team silenced IGF2BP3, levels of CENPA messenger RNA and its encoded protein fell sharply, an effect the researchers traced to destabilization of the transcript. Actinomycin D chase experiments, a classic method for measuring mRNA half-life, revealed that without IGF2BP3 standing guard, the CENPA message decayed far more rapidly. In practical terms, IGF2BP3 acts as a molecular bodyguard: by docking onto the m6A tag, it shields CENPA mRNA from the cellular degradation machinery, keeping the centromere protein continuously stocked in the tumor cell. Loss of that bodyguard leaves the cancer cell with diminished CENPA supplies and, crucially, a heightened vulnerability to paclitaxel.

That vulnerability translated into measurable changes in tumor behavior. IGF2BP3 knockdown not only increased paclitaxel sensitivity but also curtailed the migration, invasion, and clonogenic capacity of the cancer cells—the repertoire of traits that makes tumors hard to remove and prone to spread. To test whether CENPA was the critical downstream effector rather than an incidental passenger, the researchers ran a rescue experiment: they forced CENPA overexpression in IGF2BP3-silenced cells and found that the malignant capabilities returned, allowing the cells to migrate, invade, and form colonies even under paclitaxel pressure. The m6A dependency of the whole circuit was confirmed with an elegant control. When the researchers mutated the specific m6A site on CENPA mRNA, the rescue effect evaporated, demonstrating that the epitranscriptomic mark is not decorative but essential to the IGF2BP3-CENPA axis.

The story then moved from the dish to the living animal. In xenograft mouse models implanted with paclitaxel-resistant T24/R cells, silencing IGF2BP3 suppressed tumor growth and made the tumors significantly more responsive to paclitaxel treatment. Reintroducing CENPA partially reversed this effect, blunting the gains in drug sensitivity and tumor control. The in vivo results are important because they suggest that the mechanism operates not merely as a cell-culture artifact but as a genuine driver of treatment failure in a physiological setting. They also reinforce the notion that the IGF2BP3-CENPA axis sits upstream of chemoresistance rather than downstream of it, making it a plausible intervention point.

The significance of these findings lies in the convergence of two hot areas of cancer biology: epitranscriptomics and drug resistance. Over the past decade, m6A modification has emerged as a master regulator of cancer-relevant gene expression, with writers, erasers, and readers each offering potential drug targets. IGF2BPs, in particular, have been shown to stabilize transcripts supporting stemness, hypoxia adaptation, metabolism, and immune evasion in tumors. By identifying CENPA mRNA as a specific m6A-dependent target of IGF2BP3 in bladder cancer, the Nanchang-led team has connected this regulatory logic to a clinically painful problem: paclitaxel resistance in urothelial carcinoma, where poor prognosis and chemoresistance remain defining features of advanced disease. CENPA itself has already been implicated in resistance to EGFR inhibitors in lung adenocarcinoma and in suppressing ferroptosis in liver tumors, hinting that epitranscriptomic control of the centromere machinery may be a recurrent theme across cancer types.

The therapeutic implications are twofold. First, IGF2BP3 or its interaction with m6A-tagged CENPA mRNA could serve as a biomarker, helping clinicians identify patients whose tumors are likely to resist paclitaxel and who might benefit from alternative regimens or combination strategies. Second, pharmacologically disrupting the IGF2BP3-CENPA axis—whether by blocking the protein-RNA interaction, depleting IGF2BP3, or targeting upstream m6A machinery—could resensitize resistant tumors to existing chemotherapy, effectively converting nonresponders into responders. The study’s authors, led by HanJie Yi, YongQing Han, and corresponding author ShanFeng Li, suggest that targeting this axis may provide a novel strategy to overcome chemoresistance in bladder urothelial carcinoma. Substantial work remains before such strategies reach patients: the findings derive from cell lines and xenografts, and candidate inhibitors of m6A readers are only beginning to enter clinical development. Yet the study offers a clear mechanistic narrative for how bladder cancer cells weaponize a chemical tag on their own messenger RNA to endure one of medicine’s oldest spindle poisons—and in doing so, it hands researchers a precise molecular handle to pry that endurance apart.

Subject of Research: m6A-dependent stabilization of CENPA mRNA by IGF2BP3 as a mechanism of paclitaxel resistance in bladder urothelial carcinoma

Article Title: IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA

Article References: Yi, H., Han, Y., Wang, X., Li, Q., Xiong, L., & Li, S. (2026). IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA. Medical Oncology, 43(10), Article 278. https://doi.org/10.1007/s12032-026-03383-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03383-7

Keywords: bladder urothelial carcinoma, IGF2BP3, CENPA, m6A modification, paclitaxel resistance, mRNA stability, chemoresistance, epitranscriptomics, RNA-binding protein, cancer therapeutic resistance, urological cancer, xenograft models